0 results for 'Valeant Pharmaceuticals International Inc'
Cadwalader Restocks Litigation Group With Three Hires
Cadwalader, Wickersham & Taft, which has watched several notable litigators head for the exits this year, announced Monday that it had recruited a new litigation co-leader in former partner Jason Halper from Orrick, Herrington & Sutcliffe. Halper co-chaired Orrick's financial services litigation practice after joining the firm's New York office in 2014. Cadwalader also announced Monday its hire of two other litigators in London and New York.
Suits Linking Talc to Cancer Consolidated in NJ Federal Court
The Judicial Panel on Multidistrict Litigation has picked New Jersey as the site to consolidate suits nationwide linking cancer to usage of talcum powder.
FDA's Role in EpiPen Price Hikes Drawing Increased Scrutiny
Rising public outcry over dramatic price increases for the life-saving allergy auto-injector EpiPen and other medications has thrown a spotlight on the role of the U.S. Food and Drug Administration, despite its lack of direct control over drug prices and competition.
Under Scrutiny, Valeant Parts Way With Its GC
Amid plunging stock values and regulatory scrutiny, Valeant Pharmaceuticals has named Christina Ackermann as its general counsel. She replaces Robert Chai-Onn.
Litigation Slump, Leadership Shifts Take Toll at Cadwalader
Could a merger be next for Cadwalader, Wickersham & Taft?
SEC Task Force to Investigate Non-GAAP Financials
Companies that don't use “generally accepted accounting principles” (GAAP) when reporting their financials better be on their toes. They may hear from a new U.S. Securities and Exchange Commission internal task force.
Holding Activists and Proxy Advisory Firms Accountable?
In their Corporate Governance column, David A. Katz and Laura A. McIntosh write: Lawmakers are taking significant steps toward much-needed regulation of proxy advisory firms. With a bipartisan bill introduced this week, Congress outlined a comprehensive oversight framework for increasing the transparency and accountability of proxy advisory firms.
Bausch & Lomb Incorporated v. Mimetogen Pharmaceuticals, Inc.
Partial Dismissal of Breach Suit Over 'Dry Eye' Treatment's Commercialization Is Explained
Ottawa Senators Fill GC Spot With Kruger Lawyer
The Ottawa Senators don't have a coach at the moment, but they do have a new top lawyer.
How Drug Companies Can Prep for Pricing Inquiries
With spending on prescription drugs increasing, regulators and politicians are more closely scrutinizing drug pricing practices.More from ALM
- Morgan & Morgan Class Action Attorneys Detail Pathway to Success Within Cybersecurity and Data Privacy Practice 1 minute read
- Holwell Shuster & Goldberg Partners Leverage 'Hostile' Witnesses to Secure $101 Million Verdict Against Walmart 1 minute read
- Legal Speak at General Counsel Conference Midwest 2024: Mike Andolina, Partner, White & Case 1 minute read
Resources
Unlocking the Power of Early Case Assessment Workflows
Brought to you by Integreon
Download Now
Good Legal Technology is Good Business: A Case for Bringing Employment Issues In-House
Brought to you by LexisNexis®
Download Now
Insights and Strategies for Effective Succession Planning in AM Law 100 Firms
Brought to you by Gallagher
Download Now
State AI Legislation Is on the Move in 2024
Brought to you by LexisNexis®
Download Now